Cargando…
How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings
Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto‐cerebellar and meso‐cortico‐limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675406/ https://www.ncbi.nlm.nih.gov/pubmed/32643841 http://dx.doi.org/10.1002/hbm.25114 |
_version_ | 1784615864827379712 |
---|---|
author | Navarri, Xavier Afzali, Mohammad H. Lavoie, Jacob Sinha, Rajita Stein, Dan J. Momenan, Reza Veltman, Dick J Korucuoglu, Ozlem Sjoerds, Zsuzsika van Holst, Ruth J. Hester, Rob Orr, Catherine Cousijn, Janna Yucel, Murat Lorenzetti, Valentina Wiers, Reinout Jahanshad, Neda Glahn, David C. Thompson, Paul M. Mackey, Scott Conrod, Patricia J. |
author_facet | Navarri, Xavier Afzali, Mohammad H. Lavoie, Jacob Sinha, Rajita Stein, Dan J. Momenan, Reza Veltman, Dick J Korucuoglu, Ozlem Sjoerds, Zsuzsika van Holst, Ruth J. Hester, Rob Orr, Catherine Cousijn, Janna Yucel, Murat Lorenzetti, Valentina Wiers, Reinout Jahanshad, Neda Glahn, David C. Thompson, Paul M. Mackey, Scott Conrod, Patricia J. |
author_sort | Navarri, Xavier |
collection | PubMed |
description | Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto‐cerebellar and meso‐cortico‐limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been few large‐scale investigations to compare such findings. The current study uses the Enhancing Neuroimaging Genetics through Meta‐Analysis (ENIGMA) consortium method of standardising structural brain measures to quantify case–control differences and to compare brain‐correlates of substance use disorders with those published in relation to other psychiatric disorders. Using the ENIGMA protocols, we report effect sizes derived from a meta‐analysis of alcohol (seven studies, N = 798, 54% are cases) and cannabis (seven studies, N = 447, 45% are cases) dependent cases and age‐ and sex‐matched controls. We conduct linear analyses using harmonised methods to process and parcellate brain data identical to those reported in the literature for ENIGMA case–control studies of major depression disorder (MDD), schizophrenia (SCZ) and bipolar disorder so that effect sizes are optimally comparable across disorders. R elationships between substance use disorder diagnosis and subcortical grey matter volumes and cortical thickness were assessed with intracranial volume, age and sex as co‐variates . After correcting for multiple comparisons, AUD case–control meta‐analysis of subcortical regions indicated significant differences in the thalamus, hippocampus, amygdala and accumbens, with effect sizes (0.23) generally equivalent to, or larger than |0.23| those previously reported for other psychiatric disorders (except for the pallidum and putamen). On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri. Meta‐analysis of CUD case–control studies indicated reliable reductions in amygdala, accumbens and hippocampus volumes, with the former effect size comparable to, and the latter effect size around half of that reported for alcohol and SCZ. CUD was associated with lower cortical thickness in the frontal regions, particularly the medial orbitofrontal region, but this effect was not significant after correcting for multiple testing. This study allowed for an unbiased cross‐disorder comparison of brain correlates of substance use disorders and showed alcohol‐related brain anomalies equivalent in effect size to that found in SCZ in several subcortical and cortical regions and significantly greater alterations than those found in MDD in several subcortical and cortical regions. Although modest, CUD results overlapped with findings reported for AUD and other psychiatric conditions, but appear to be most robustly related to reduce thickness of the medial orbitofrontal cortex. |
format | Online Article Text |
id | pubmed-8675406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86754062021-12-27 How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings Navarri, Xavier Afzali, Mohammad H. Lavoie, Jacob Sinha, Rajita Stein, Dan J. Momenan, Reza Veltman, Dick J Korucuoglu, Ozlem Sjoerds, Zsuzsika van Holst, Ruth J. Hester, Rob Orr, Catherine Cousijn, Janna Yucel, Murat Lorenzetti, Valentina Wiers, Reinout Jahanshad, Neda Glahn, David C. Thompson, Paul M. Mackey, Scott Conrod, Patricia J. Hum Brain Mapp Research Articles Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto‐cerebellar and meso‐cortico‐limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been few large‐scale investigations to compare such findings. The current study uses the Enhancing Neuroimaging Genetics through Meta‐Analysis (ENIGMA) consortium method of standardising structural brain measures to quantify case–control differences and to compare brain‐correlates of substance use disorders with those published in relation to other psychiatric disorders. Using the ENIGMA protocols, we report effect sizes derived from a meta‐analysis of alcohol (seven studies, N = 798, 54% are cases) and cannabis (seven studies, N = 447, 45% are cases) dependent cases and age‐ and sex‐matched controls. We conduct linear analyses using harmonised methods to process and parcellate brain data identical to those reported in the literature for ENIGMA case–control studies of major depression disorder (MDD), schizophrenia (SCZ) and bipolar disorder so that effect sizes are optimally comparable across disorders. R elationships between substance use disorder diagnosis and subcortical grey matter volumes and cortical thickness were assessed with intracranial volume, age and sex as co‐variates . After correcting for multiple comparisons, AUD case–control meta‐analysis of subcortical regions indicated significant differences in the thalamus, hippocampus, amygdala and accumbens, with effect sizes (0.23) generally equivalent to, or larger than |0.23| those previously reported for other psychiatric disorders (except for the pallidum and putamen). On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri. Meta‐analysis of CUD case–control studies indicated reliable reductions in amygdala, accumbens and hippocampus volumes, with the former effect size comparable to, and the latter effect size around half of that reported for alcohol and SCZ. CUD was associated with lower cortical thickness in the frontal regions, particularly the medial orbitofrontal region, but this effect was not significant after correcting for multiple testing. This study allowed for an unbiased cross‐disorder comparison of brain correlates of substance use disorders and showed alcohol‐related brain anomalies equivalent in effect size to that found in SCZ in several subcortical and cortical regions and significantly greater alterations than those found in MDD in several subcortical and cortical regions. Although modest, CUD results overlapped with findings reported for AUD and other psychiatric conditions, but appear to be most robustly related to reduce thickness of the medial orbitofrontal cortex. John Wiley & Sons, Inc. 2020-07-09 /pmc/articles/PMC8675406/ /pubmed/32643841 http://dx.doi.org/10.1002/hbm.25114 Text en © 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Navarri, Xavier Afzali, Mohammad H. Lavoie, Jacob Sinha, Rajita Stein, Dan J. Momenan, Reza Veltman, Dick J Korucuoglu, Ozlem Sjoerds, Zsuzsika van Holst, Ruth J. Hester, Rob Orr, Catherine Cousijn, Janna Yucel, Murat Lorenzetti, Valentina Wiers, Reinout Jahanshad, Neda Glahn, David C. Thompson, Paul M. Mackey, Scott Conrod, Patricia J. How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings |
title | How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings |
title_full | How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings |
title_fullStr | How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings |
title_full_unstemmed | How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings |
title_short | How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross‐disorder meta‐analytic comparison using the ENIGMA consortium findings |
title_sort | how do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? a cross‐disorder meta‐analytic comparison using the enigma consortium findings |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675406/ https://www.ncbi.nlm.nih.gov/pubmed/32643841 http://dx.doi.org/10.1002/hbm.25114 |
work_keys_str_mv | AT navarrixavier howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT afzalimohammadh howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT lavoiejacob howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT sinharajita howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT steindanj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT momenanreza howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT veltmandickj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT korucuogluozlem howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT sjoerdszsuzsika howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT vanholstruthj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT hesterrob howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT orrcatherine howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT cousijnjanna howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT yucelmurat howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT lorenzettivalentina howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT wiersreinout howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT jahanshadneda howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT glahndavidc howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT thompsonpaulm howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT mackeyscott howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings AT conrodpatriciaj howdosubstanceusedisorderscomparetootherpsychiatricconditionsonstructuralbrainabnormalitiesacrossdisordermetaanalyticcomparisonusingtheenigmaconsortiumfindings |